Literature DB >> 23462799

A cross-sectional multicenter study of cognitive and behavioural features in multiple system atrophy patients of the parkinsonian and cerebellar type.

C Siri1, S Duerr, M Canesi, M Delazer, R Esselink, B R Bloem, T Gurevich, M Balas, N Giladi, P Santacruz, F Marti, E Tolosa, A Rubino, G Meco, W Poewe, G Pezzoli, G Wenning, A Antonini.   

Abstract

Imaging and neuropathology studies have demonstrated significant abnormalities not only in subcortical, but also in cortical regions of patients with multiple system atrophy (MSA). This raises the possibility that cognitive dysfunction may contribute to the clinical spectrum of this disorder to a greater extent than it is currently not widely appreciated. In this cross-sectional multicenter study from the European multiple system atrophy study group ( http://www.emsa-sg.org ), we applied an extensive neuropsychological test battery in a series of 61 clinically diagnosed probable MSA patients. The results demonstrated that general cognitive decline as assessed by MMSE was uncommon (2 out of 61 patients <24). In contrast, frontal lobe-related functions (as measured by FAB) were impaired in 41 % of patients, with abstract reasoning and sustained attention less compromised. This pattern was similar to our control group of 20 patients with Parkinson's disease (matched for disease duration and age at onset). There was no difference in cognitive performance between MSA patients with the parkinsonian versus the cerebellar variant. Behaviourally, MSA patients had greater depression than PD and in the case of MSA of the cerebellar variant significantly lower anxiety. Our data show that cognitive abnormalities are relatively frequent in multiple system atrophy and this involves primarily frontal-executive functions. Their contribution to clinical disability and disease progression needs to be addressed in larger prospective studies.

Entities:  

Mesh:

Year:  2013        PMID: 23462799     DOI: 10.1007/s00702-013-0997-x

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  27 in total

1.  The Frontal Assessment Battery (FAB): normative values in an Italian population sample.

Authors:  I Appollonio; M Leone; V Isella; F Piamarta; T Consoli; M L Villa; E Forapani; A Russo; P Nichelli
Journal:  Neurol Sci       Date:  2005-06       Impact factor: 3.307

2.  Raven's coloured progressive matrices: normative values on 305 adult normal controls.

Authors:  A Basso; E Capitani; M Laiacona
Journal:  Funct Neurol       Date:  1987 Apr-Jun

3.  The FAB: a Frontal Assessment Battery at bedside.

Authors:  B Dubois; A Slachevsky; I Litvan; B Pillon
Journal:  Neurology       Date:  2000-12-12       Impact factor: 9.910

4.  Regional brain volumes distinguish PSP, MSA-P, and PD: MRI-based clinico-radiological correlations.

Authors:  Dominic C Paviour; Shona L Price; Marjan Jahanshahi; Andrew J Lees; Nick C Fox
Journal:  Mov Disord       Date:  2006-07       Impact factor: 10.338

5.  Neuropsychological follow up in patients with Parkinson's disease, striatonigral degeneration-type multisystem atrophy, and progressive supranuclear palsy.

Authors:  P Soliveri; D Monza; D Paridi; F Carella; S Genitrini; D Testa; F Girotti
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-09       Impact factor: 10.154

6.  Assessment of dementia in patients with multiple system atrophy.

Authors:  M Kitayama; K Wada-Isoe; Y Irizawa; K Nakashima
Journal:  Eur J Neurol       Date:  2009-02-19       Impact factor: 6.089

7.  Cognitive deficits in progressive supranuclear palsy, Parkinson's disease, and multiple system atrophy in tests sensitive to frontal lobe dysfunction.

Authors:  T W Robbins; M James; A M Owen; K W Lange; A J Lees; P N Leigh; C D Marsden; N P Quinn; B A Summers
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-01       Impact factor: 10.154

8.  The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia.

Authors:  J L Cummings; M Mega; K Gray; S Rosenberg-Thompson; D A Carusi; J Gornbein
Journal:  Neurology       Date:  1994-12       Impact factor: 9.910

9.  Cognition in multiple system atrophy: neuropsychological profile and interaction with mood.

Authors:  Meirav Balas; Yacov Balash; Nir Giladi; Tanya Gurevich
Journal:  J Neural Transm (Vienna)       Date:  2010-01-21       Impact factor: 3.575

10.  Second consensus statement on the diagnosis of multiple system atrophy.

Authors:  S Gilman; G K Wenning; P A Low; D J Brooks; C J Mathias; J Q Trojanowski; N W Wood; C Colosimo; A Dürr; C J Fowler; H Kaufmann; T Klockgether; A Lees; W Poewe; N Quinn; T Revesz; D Robertson; P Sandroni; K Seppi; M Vidailhet
Journal:  Neurology       Date:  2008-08-26       Impact factor: 9.910

View more
  29 in total

1.  Cognitive impairment and structural brain damage in multiple system atrophy-parkinsonian variant.

Authors:  Francesca Caso; Elisa Canu; Milica Jecmenica Lukic; Igor N Petrovic; Andrea Fontana; Ivan Nikolic; Vladimir S Kostic; Massimo Filippi; Federica Agosta
Journal:  J Neurol       Date:  2019-09-26       Impact factor: 4.849

Review 2.  Cognitive impairment in multiple system atrophy: a position statement by the Neuropsychology Task Force of the MDS Multiple System Atrophy (MODIMSA) study group.

Authors:  Iva Stankovic; Florian Krismer; Aleksandar Jesic; Angelo Antonini; Thomas Benke; Richard G Brown; David J Burn; Janice L Holton; Horacio Kaufmann; Vladimir S Kostic; Helen Ling; Wassilios G Meissner; Werner Poewe; Marija Semnic; Klaus Seppi; Atsushi Takeda; Daniel Weintraub; Gregor K Wenning
Journal:  Mov Disord       Date:  2014-04-18       Impact factor: 10.338

Review 3.  Fragile X-associated tremor/ataxia syndrome: phenotypic comparisons with other movement disorders.

Authors:  Erin E Robertson; Deborah A Hall; Andrew R McAsey; Joan A O'Keefe
Journal:  Clin Neuropsychol       Date:  2016-08       Impact factor: 3.535

4.  Muscle Decline in Aging and Neuromuscular Disorders - Mechanisms and Countermeasures: Terme Euganee, Padova (Italy), April 13-16, 2016.

Authors: 
Journal:  Eur J Transl Myol       Date:  2016-03-31

5.  Profile of cognitive impairment and underlying pathology in multiple system atrophy.

Authors:  Shunsuke Koga; Adam Parks; Ryan J Uitti; Jay A van Gerpen; William P Cheshire; Zbigniew K Wszolek; Dennis W Dickson
Journal:  Mov Disord       Date:  2016-11-15       Impact factor: 10.338

6.  Brain structural profile of multiple system atrophy patients with cognitive impairment.

Authors:  Eleonora Fiorenzato; Luca Weis; Klaus Seppi; Marco Onofrj; Pietro Cortelli; Stefano Zanigni; Caterina Tonon; Horacio Kaufmann; Timothy Michael Shepherd; Werner Poewe; Florian Krismer; Gregor Wenning; Angelo Antonini; Roberta Biundo
Journal:  J Neural Transm (Vienna)       Date:  2016-10-24       Impact factor: 3.575

7.  Alterations in Cognition-Related Cerebello-Cerebral Networks in Multiple System Atrophy.

Authors:  Kazuya Kawabata; Kazuhiro Hara; Hirohisa Watanabe; Epifanio Bagarinao; Aya Ogura; Michihito Masuda; Takamasa Yokoi; Toshiyasu Kato; Reiko Ohdake; Mizuki Ito; Masahisa Katsuno; Gen Sobue
Journal:  Cerebellum       Date:  2019-08       Impact factor: 3.847

8.  Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE) performance in progressive supranuclear palsy and multiple system atrophy.

Authors:  Eleonora Fiorenzato; Luca Weis; Cristian Falup-Pecurariu; Stefania Diaconu; Chiara Siri; Elisa Reali; Gianni Pezzoli; Patrizia Bisiacchi; Angelo Antonini; Roberta Biundo
Journal:  J Neural Transm (Vienna)       Date:  2016-06-22       Impact factor: 3.575

9.  Clinical outcomes of two main variants of progressive supranuclear palsy and multiple system atrophy: a prospective natural history study.

Authors:  Milica Jecmenica-Lukic; Igor N Petrovic; Tatjana Pekmezovic; Vladimir S Kostic
Journal:  J Neurol       Date:  2014-06-03       Impact factor: 4.849

10.  An update on the cerebellar subtype of multiple system atrophy.

Authors:  Ludovico Ciolli; Florian Krismer; Ferdinando Nicoletti; Gregor K Wenning
Journal:  Cerebellum Ataxias       Date:  2014-10-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.